Cat. No.: HY-13683

Mifepristone

(Synonyms: RU486; RU 38486)

76 Cited Publications

Customer Review

Based on 76 publication(s) in Google Scholar

Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay.

For research use only. We do not sell to patients.

Purity: 99.88%
CAS No.: 84371-65-3
Formula: C₂₉H₃₅NO₂
Molecular Weight:429.59

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Mifepristone Chemical Structure

CAS No.: 84371-65-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (76)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay^[1].

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

All NO Synthase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	1.6 nM Compound: Mifepristone	Antagonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of corticoid-induced GRE-linked luciferase reporter gene activity Antagonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of corticoid-induced GRE-linked luciferase reporter gene activity	[PMID: 17169557]
A549	IC₅₀	1.6 nM Compound: Mifepristone	Antagonist activity at human glucocorticoid receptor assessed as inhibition of corticoid-induced transcription in human A549 cells by GRE-linked luciferase reporter gene assay Antagonist activity at human glucocorticoid receptor assessed as inhibition of corticoid-induced transcription in human A549 cells by GRE-linked luciferase reporter gene assay	[PMID: 17317167]
A549	IC₅₀	6 nM Compound: 1, mifepristone,RU-486	Antagonist activity at glucocorticoid receptor expressed in A549 cells assessed as inhibition of corticoid-induced gene transcription by luciferase reporter gene assay Antagonist activity at glucocorticoid receptor expressed in A549 cells assessed as inhibition of corticoid-induced gene transcription by luciferase reporter gene assay	[PMID: 17855092]
A549	IC₅₀	1.6 nM Compound: Mifepristone	Antagonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of corticoid-induced transcription after 16 hrs by glucocorticoid response element-driven luciferase reporter gene assay Antagonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of corticoid-induced transcription after 16 hrs by glucocorticoid response element-driven luciferase reporter gene assay	[PMID: 19217285]
CHO	IC₅₀	5 nM Compound: 1 Mifepristone - RU-486	Inhibition of Dexamethasone stimulated transcriptional activity in CHO cells expressing glucocorticoid receptor Inhibition of Dexamethasone stimulated transcriptional activity in CHO cells expressing glucocorticoid receptor	[PMID: 12824023]
CHO	IC₅₀	5 nM Compound: 1, RU-486	Activity at GR expressed in CHO cells assessed as decrease in dexamethasone-stimulated alkaline phosphatase production by GRAF assay Activity at GR expressed in CHO cells assessed as decrease in dexamethasone-stimulated alkaline phosphatase production by GRAF assay	[PMID: 16987661]
CHO-K1	IC₅₀	0.008 nM Compound: 4 (Mifepristone)	Inhibition of CHO-K1 cells expressing glucocorticoid receptor Inhibition of CHO-K1 cells expressing glucocorticoid receptor	[PMID: 15456242]
CHO-K1	IC₅₀	7.8 nM Compound: 4 (Mifepristone)	Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor	[PMID: 15456242]
CHO-K1	IC₅₀	0.4 nM Compound: 1	Antagonist activity at human progesterone receptor expressed in CHO-K1 cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay Antagonist activity at human progesterone receptor expressed in CHO-K1 cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay	[PMID: 31274313]
CHO-K1	IC₅₀	3.26 nM Compound: 1	Antagonist activity at human glucocorticoid receptor expressed in CHO-K1 cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay Antagonist activity at human glucocorticoid receptor expressed in CHO-K1 cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay	[PMID: 31274313]
CHO-K1	IC₅₀	3.5 nM Compound: 1	Antagonist activity at human glucocorticoid receptor expressed in CHO-K1 cells assessed as inhibition of glucocorticoid receptor-dexamethasone coactivator protein-protein interaction incubated for 24 hrs by bioluminescence assay Antagonist activity at human glucocorticoid receptor expressed in CHO-K1 cells assessed as inhibition of glucocorticoid receptor-dexamethasone coactivator protein-protein interaction incubated for 24 hrs by bioluminescence assay	[PMID: 31274313]
COS-7	IC₅₀	0.6 nM Compound: 3, mifepristone	Antagonist activity at human GR ligand binding domain expressed in african green monkey COS7 cells in presence of Dexamethasone by Gal4 hybrid assay Antagonist activity at human GR ligand binding domain expressed in african green monkey COS7 cells in presence of Dexamethasone by Gal4 hybrid assay	[PMID: 18318463]
COS-7	IC₅₀	6.9 nM Compound: 3, mifepristone	Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay	[PMID: 18318463]
COS-7	IC₅₀	0.6 nM Compound: 1, mifepristone	Antagonist activity at cloned glucocorticoid receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay Antagonist activity at cloned glucocorticoid receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay	[PMID: 18504132]
COS-7	IC₅₀	590 nM Compound: 1, mifepristone	Antagonist activity at cloned mineralocorticoid receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay Antagonist activity at cloned mineralocorticoid receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay	[PMID: 18504132]
COS-7	IC₅₀	6.9 nM Compound: 1, mifepristone	Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay	[PMID: 18504132]
COS-7	IC₅₀	5 μM Compound: 1, mifepristone	Antagonist activity at cloned estrogen receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay Antagonist activity at cloned estrogen receptor-ligand binding domain expressed in african green monkey COS7 cells by GAL4 luciferase reporter assay	[PMID: 18504132]
COS-7	IC₅₀	3.2 nM Compound: Mifepristone	Antagonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay Antagonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay	[PMID: 19863083]
CV-1	IC₅₀	10 nM Compound: mifepristone RU-38486 RU-486	In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor	[PMID: 11150172]
CV-1	IC₅₀	0.3 nM Compound: 1	Antagonist activity against progesterone receptor (PR) using PRE-luciferase plasmid co-transfected CV-1 cells Antagonist activity against progesterone receptor (PR) using PRE-luciferase plasmid co-transfected CV-1 cells	[PMID: 12238914]
CV-1	IC₅₀	0.3 nM Compound: Mifepristone	Inhibitory concentration for antagonistic activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells Inhibitory concentration for antagonistic activity towards human progesterone receptor (hPR) using the cotransfection assay in CV-1 cells	[PMID: 12781197]
CV-1	EC₅₀	0.3 nM Compound: Mifepristone	Antagonistic activity at human progesterone receptor in CV-1 cells. Antagonistic activity at human progesterone receptor in CV-1 cells.	[PMID: 12781198]
CV-1	EC₅₀	0.6 nM Compound: mifepristone	Antagonist activity at human GR expressed in CV1 cells by GRE activation assay Antagonist activity at human GR expressed in CV1 cells by GRE activation assay	[PMID: 17705362]
CV-1	EC₅₀	>10000 nM Compound: RU-486	Agonist activity at human ERbeta expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human ERbeta expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	>10000 nM Compound: RU-486	Agonist activity at human mineralocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human mineralocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	>10000 nM Compound: RU-486	Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	10 nM Compound: RU-486	Agonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	872 nM Compound: RU-486	Agonist activity at human glucocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human glucocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	0.6 nM Compound: RU-486	Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay Antagonist activity at human progesterone receptor B expressed in african green monkey CV1 cells co-transfected with MMTV-Luc assessed as effect on progesterone-induced activity by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	0.95 nM Compound: RU-486	Antagonist activity at human glucocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay Antagonist activity at human glucocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	1 nM Compound: RU-486	Antagonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay Antagonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	812 nM Compound: RU-486	Antagonist activity at human ERbeta expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc by luciferase reporter gene assay Antagonist activity at human ERbeta expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc by luciferase reporter gene assay	[PMID: 20510622]
CV-1	EC₅₀	>10000 nM Compound: RU-486	Agonist activity at human ERalpha expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc after 24 hrs by luciferase reporter gene assay Agonist activity at human ERalpha expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc after 24 hrs by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	>1000 nM Compound: RU-486	Antagonist activity at human ERalpha expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc by luciferase reporter gene assay Antagonist activity at human ERalpha expressed in african green monkey CV1 cells co-transfected with ERE-MMTV-Luc by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	>10000 nM Compound: RU-486	Antagonist activity at human mineralocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay Antagonist activity at human mineralocorticoid receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay	[PMID: 20510622]
CV-1	IC₅₀	0.18 nM Compound: RU-486 Mifepristone	Concentration required to give half-maximal inhibition against human Progesterone receptor B isoform in co-transfected CV-1 cell lines. Concentration required to give half-maximal inhibition against human Progesterone receptor B isoform in co-transfected CV-1 cell lines.	[PMID: 8627601]
CV-1	IC₅₀	0.18 nM Compound: RU-486 (Mifepristone)	Antagonistic activity against human progesterone receptor B (hPR-B) in co-transfected CV-1 cells. Antagonistic activity against human progesterone receptor B (hPR-B) in co-transfected CV-1 cells.	[PMID: 9484511]
CV-1	IC₅₀	5 nM Compound: RU-486 (Mifepristone)	Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells. Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.	[PMID: 9484511]
CV-1	IC₅₀	0.3 nM Compound: 1	Antagonist activity against human progesterone receptor B (hPR-B) in co-transfected CV-1 cells Antagonist activity against human progesterone receptor B (hPR-B) in co-transfected CV-1 cells	[PMID: 9873612]
HCC1937	IC₅₀	>20 μM Compound: 1	Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay	[PMID: 29407962]
HEK293	IC₅₀	0.298 nM Compound: MIF	Antagonist activity against glucocorticoid receptor (unknown origin) expressed in HEK293 cells by GRE-dependent luciferase reporter gene assay Antagonist activity against glucocorticoid receptor (unknown origin) expressed in HEK293 cells by GRE-dependent luciferase reporter gene assay	[PMID: 26218343]
HeLa	EC₅₀	2 nM Compound: RU-486 (Mifepristone)	Effective concentration against inhibition of Dexamethasone induced glucocorticoid receptor transactivation of mouse mammary tumor virus luciferase gene in HeLa cells Effective concentration against inhibition of Dexamethasone induced glucocorticoid receptor transactivation of mouse mammary tumor virus luciferase gene in HeLa cells	[PMID: 16112571]
Hepatocyte	IC₅₀	0.41 μM Compound: 1 Mifepristone - RU-486	Inhibition of prednisilone-induced tyrosine aminotransferase (TAT) activity in rat hepatocytes Inhibition of prednisilone-induced tyrosine aminotransferase (TAT) activity in rat hepatocytes	[PMID: 12824023]
Hepatocyte	IC₅₀	0.27 μM Compound: 1	Inhibition of dexamethasone-induced glucocorticoid receptor mediated tyrosine aminotransferase in rat hepatocytes Inhibition of dexamethasone-induced glucocorticoid receptor mediated tyrosine aminotransferase in rat hepatocytes	[PMID: 15261265]
Hepatocyte	IC₅₀	0.27 μM Compound: RU-486 (Mifepristone)	Inhibition of dexamethasone-induced GR-mediated tyrosine amino transferase activity in rat hepatocytes Inhibition of dexamethasone-induced GR-mediated tyrosine amino transferase activity in rat hepatocytes	[PMID: 15261266]
K562/R7	IC₅₀	0.9 μM Compound: RU486	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	[PMID: 25634041]
LNCaP	EC₅₀	11.9 nM Compound: 1	Agonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay Agonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay	[PMID: 31274313]
MCF7	IC₅₀	24.03 μM Compound: Mifepristone	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by CCK-8 assay	[PMID: 33461148]
NIH3T3	IC₅₀	2.2 nM Compound: mifepristone RU-38486 RU-486	In vitro antagonist potency in transactivation assay in NIH3T3 cells expressing glucocorticoid receptor In vitro antagonist potency in transactivation assay in NIH3T3 cells expressing glucocorticoid receptor	[PMID: 11150172]
SUM149PT	IC₅₀	15 μM Compound: 1	Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay	[PMID: 29407962]
T47D	IC₅₀	0.2 nM Compound: Mifepristone	Inhibitory concentration against progesterone stimulated alkaline phosphatase activity in T47D human breast carcinoma cell line Inhibitory concentration against progesterone stimulated alkaline phosphatase activity in T47D human breast carcinoma cell line	[PMID: 11591515]
T47D	IC₅₀	0.2 nM Compound: Mifepristone RU-486	Antagonistic activity against Progesterone receptor (PR) in transcriptional activation assay in human T47D breast carcinoma cell line Antagonistic activity against Progesterone receptor (PR) in transcriptional activation assay in human T47D breast carcinoma cell line	[PMID: 11859003]
T47D	IC₅₀	0.13 nM Compound: 1	Antagonist activity against progesterone receptor (PR) in an alkaline phosphatase assay in the T47D human breast carcinoma cell line Antagonist activity against progesterone receptor (PR) in an alkaline phosphatase assay in the T47D human breast carcinoma cell line	[PMID: 12238914]
T47D	IC₅₀	0.1 nM Compound: 2	Progesterone receptor antagonist activity based on its ability to block progesterone induced alkaline phosphatase in the human breast cancer cell line T47D Progesterone receptor antagonist activity based on its ability to block progesterone induced alkaline phosphatase in the human breast cancer cell line T47D	[PMID: 12419390]
T47D	IC₅₀	3.3 nM Compound: Mifepristone	Inhibition of human progesterone receptor activation in T47D human breast cancer cell. Inhibition of human progesterone receptor activation in T47D human breast cancer cell.	[PMID: 12781198]
T47D	IC₅₀	0.7 nM Compound: Mif (Mifepristone)	Displacement of [3H]progesterone at progesterone receptor of T47D cells Displacement of [3H]progesterone at progesterone receptor of T47D cells	[PMID: 15081005]
T47D	IC₅₀	1.4 nM Compound: Mifepristone	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	[PMID: 17169557]
T47D	IC₅₀	1.4 nM Compound: Mifepristone	Antagonist activity at human progesterone receptor assessed as inhibition of alkaline phosphatase activity in human T47D cells Antagonist activity at human progesterone receptor assessed as inhibition of alkaline phosphatase activity in human T47D cells	[PMID: 17317167]
T47D	IC₅₀	0.054 nM Compound: 1, mifepristone,RU-486	Antagonist activity at progesterone receptor expressed in human T47D cells assessed as inhibition of promegestone-induced alkaline phosphatase activity Antagonist activity at progesterone receptor expressed in human T47D cells assessed as inhibition of promegestone-induced alkaline phosphatase activity	[PMID: 17855092]
T47D	IC₅₀	0.2 nM Compound: 3, mifepristone	Antagonist activity at human PR expressed in human T47D cells assessed as inhibition of progesterone induced alkaline phosphatase Antagonist activity at human PR expressed in human T47D cells assessed as inhibition of progesterone induced alkaline phosphatase	[PMID: 18318463]
T47D	IC₅₀	0.6 nM Compound: 3, mifepristone	Displacement of [3H]R5020 from human PR in human T47D cells by whole cell assay Displacement of [3H]R5020 from human PR in human T47D cells by whole cell assay	[PMID: 18318463]
T47D	IC₅₀	0.2 nM Compound: 1, mifepristone	Inhibition of progesterone receptor mediated progesterone-induced alkaline phosphatase activity in human T47D cells Inhibition of progesterone receptor mediated progesterone-induced alkaline phosphatase activity in human T47D cells	[PMID: 18504132]
T47D	IC₅₀	0.2 nM Compound: 2	Antagonist activity at progesterone receptor assessed as progesterone-induced alkaline phosphatase activity in human T47D cells Antagonist activity at progesterone receptor assessed as progesterone-induced alkaline phosphatase activity in human T47D cells	[PMID: 18722119]
T47D	IC₅₀	0.045 nM Compound: 1, RU-486	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity after 48 hrs Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity after 48 hrs	[PMID: 19216549]
T47D	IC₅₀	1.4 nM Compound: Mifepristone	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	[PMID: 19217285]
T47D	IC₅₀	0.05 nM Compound: 10	Antiprogestagenic activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity Antiprogestagenic activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	[PMID: 20149664]
T47D	IC₅₀	0.2 nM Compound: 2	Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity Antagonist activity at progesterone receptor in human T47D cells assessed as inhibition of progesterone-induced alkaline phosphatase activity	[PMID: 20638844]

In Vitro

The discovery of the first competitive progesterone antagonist, Mifepristone, has stimulated an intense search for more potent and more selective antiprogestins^[1]. Cell growth is evaluated after 4 days of exposure to Mifepristone at 10 μM, a concentration close to the plasma concentration achievable in humans. The antiproliferative effect of NSC 119875 is potentiated when administered in combination with Mifepristone in HeLa cells. The IC₅₀ of NSC 119875 in combination with Mifepristone is lower (14.2 μM) than that of NSC 119875 alone (34.2 μM) in HeLa cells with an approximately 2.5-fold difference. After treatment with Mifepristone, the accumulation of intracellular NSC 119875 in HeLa cells is 2-fold greater, representing a significant difference (p=0.009), compare with NSC 119875 alone from 0.79 to 1.52 μg/mg of protein^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The cervix tumor xenograft models are treated with NSC 119875 alone, there is a tumor growth inhibition compare with control group. However, the tumor weight loss is even more significant (p<0.05) with the combination of NSC 119875 and Mifepristone at the doses used, showing a decrease of ~50% compared with the treatments alone by the end of the study^[2]. Adult male Sprague-Dawley rats are subjected to a 4-day binge-like EtOH administration regimen (3 to 5 g/kg/i.g. every 8 hours designed to produce peak blood EtOH levels (BELs) of <300 mg/dL). Subgroups of animals receive s.c. injection of Mifepristone (20 or 40 mg/kg in peanut oil). Although Mifepristone produces no significant changes in behavior of EtOH-na?ve animals, pretreatment with Mifepristone (40 mg/kg) significantly reducesthe severity of EtOH withdrawal. Asignificant interaction between diet and drug, F(5,55)=3.92, p<0.05, such that EtOH-treated animals receiving vehicle or 20 mg/kg of Mifepristone displayssignificantly more signs of EtOH withdrawal than does EtOH-na?ve animals receiving the same drug treatment. Importantly, treatment with 40 mg/kg of Mifepristone significantly reduces the severity of EtOH withdrawal, in a dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 84371-65-3
Appearance Solid
Molecular Weight 429.59
Formula C₂₉H₃₅NO₂
Color White to light yellow
SMILES

C[C@@]12[C@@](C#CC)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C2)=O
Synonyms

RU486; RU 38486
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (76)

All RT-PCRCell Proliferation/Viability AssayWBIF

Sort by:

Journal Impact Factor

Science

Unstructured transcription factor interactions enable emergent specificity. [Abstract]

2026 May 28;392(6801):eaeb6487. PMID: 41855276
Cell Metab

Ferroplasticity drives social isolation-induced anxiety via a ventral hippocampal iron-α-synuclein axis. [Abstract]

2026 Jan 27:S1550-4131(25)00586-8. PMID: 41605214
Immunity

Hyperactivation of sympathetic nerves fuels basophil infiltration in atopic dermatitis. [Abstract]

2026 Mar 10;59(3):598-617.e11. PMID: 41722568
Immunity

Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]

2024 Feb 13;57(2):364-378.e9. PMID: 38301651
Cell Mol Immunol

Acute stress alleviates type 2 lung inflammation by restricting ILC2s through corticosterone-glucocorticoid receptor signaling. [Abstract]

2026 May;23(5):546-559. PMID: 41927788
Nat Commun

Hypothalamus-sympathetic-liver axis mediates the early phase of stress-induced hyperglycemia in the male mice. [Abstract]

2024 Oct 5;15(1):8632. PMID: 39366937
ACS Nano

Dexamethasone-Integrated Mesenchymal Stem Cells for Systemic Lupus Erythematosus Treatment via Multiple Immunomodulatory Mechanisms. [Abstract]

2024 May 8. PMID: 38720584
J Adv Res

OSBPL6 protects against demyelination and behavioral disorder via promoting cholesterol transport in oligodendrocyte. [Abstract]

2026 Jan 26:S2090-1232(26)00091-3. PMID: 41605285
Cell Discov

Psychological stress-induced systemic corticosterone directly sabotages intestinal stem cells and exacerbates colitis. [Abstract]

2025 May 13;11(1):46. PMID: 40360481
Sci Transl Med

Chemical perturbations reveal that RUVBL2 regulates the circadian phase in mammals. [Abstract]

2020 May 6;12(542):eaba0769. PMID: 32376767
Acta Pharm Sin B

Gestational dexamethasone exposure impacts hippocampal excitatory synaptic transmission and learning and memory function with transgenerational effects. [Abstract]

2023 Sep;13(9):3708-3727. PMID: 37719378
Adv Sci (Weinh)

Adrenal High-Expressional CYP27A1 Mediates Bile Acid Increase and Functional Impairment in Adult Male Offspring by Prenatal Dexamethasone Exposure. [Abstract]

2025 Apr;12(14):e2413299. PMID: 39950753
Cell Death Dis

Calcium overload induced mitochondrial and lysosomal dysfunction is regulated by Tousled-like kinase in a-synucleinopathy. [Abstract]

2026 Jan 8;17(1):10. PMID: 41507136
Phytomedicine

GSTM2 as the molecular linking of depression-driven colon cancer progression and chemoresistance: Reversal by Sinisan. [Abstract]

2026 Jun:155:158113. PMID: 41962265
Phytomedicine

20(S)-Protopanaxadiol regulating glucocorticoid receptor attenuates ischemic stroke injury by alleviating the autophagy-lysosomal pathway dysfunction and neuroinflammation. [Abstract]

2026 Jan:150:157768. PMID: 41499936
Phytomedicine

Paris polyphylla ethanol extract and polyphyllin I ameliorate adenomyosis by inhibiting epithelial-mesenchymal transition. [Abstract]

2024 May:127:155461. PMID: 38452697

Mifepristone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 May:127:155461. [Abstract]

Mifepristone (0-64 μM; 48 h). Impact of mifepristone on AMDCs cytotoxicity.
Arch Toxicol

Intrauterine RAS programming alteration-mediated susceptibility and heritability of temporal lobe epilepsy in male offspring rats induced by prenatal dexamethasone exposure. [Abstract]

2020 Sep;94(9):3201-3215. PMID: 32494933
Environ Int

Dexamethasone as an emerging environmental pollutant: Disruption of cholesterol-dependent synaptogenesis in the hippocampus and subsequent neurobehavioral impacts in offspring. [Abstract]

2024 Oct:192:109064. PMID: 39413532
Oncogene

Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway. [Abstract]

2021 Sep;40(35):5367-5378. PMID: 34272474
Int J Biol Macromol

Estrogen and glucocorticoid promote the lactoferrin synthesis and secretion ability of bovine mammary epithelial cells through ER and GR signaling pathways. [Abstract]

2025 Feb 2:140636. PMID: 39904446

Mifepristone purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Feb 2:140636. [Abstract]

Mifepristone (10  μM; 1  h). Results of qRT-PCR to detect the mRNA levels of LF in BMECs.
Antioxidants (Basel)

Continuous Monochromatic Blue Light Exacerbates High-Fat Diet-Induced Kidney Injury via Corticosterone-Mediated Oxidative Stress. [Abstract]

2023 Apr 28;12(5):1018. PMID: 37237884
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233

Mifepristone purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]

HT1080 and HUH7 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).
Curr Biol

Cross-modal cortical circuit for sound sensitivity in neuropathic pain. [Abstract]

2025 Feb 24;35(4):831-842.e5. PMID: 39889698
Cell Rep

Fat- and sugar-induced signals regulate sweet and fat taste perception in Drosophila. [Abstract]

2023 Nov 6;42(11):113387. PMID: 37934669
Br J Pharmacol

Ginsenoside compound K up-regulates β-subunits of long-chain L-3-hydroxyacyl-CoA (HADHB) to promote fatty acid oxidation recovery and improve the balance of macrophage polarization in mice with ulcerative colitis. [Abstract]

2026 Jul;183(13):3633-3650. PMID: 41918496
Brain Behav Immun

Chronic psychological stress-orchestrated glial-ILC3 circuit exacerbates intestinal inflammation and depression. [Abstract]

2025 Sep 21:130:106118. PMID: 40987409
Br J Pharmacol

Protopanaxadiol alleviates neuropathic pain by spinal microglial dynorphin A expression following glucocorticoid receptor activation. [Abstract]

2021 Aug;178(15):2976-2997. PMID: 33786848
J Ethnopharmacol

Bushen Antai recipe attenuates recurrent spontaneous abortion by activating VEGFA/p-AKT/SESN2 to restore trophoblast endoplasmic reticulum homeostasis. [Abstract]

2026 May 25:369:121902. PMID: 42190766
Hum Reprod

Scribble downregulation in adenomyosis compromises endometrial stromal decidualization by decreasing FOXO1 expression. [Abstract]

2021 Dec 27;37(1):93-108. PMID: 34746956
CNS Neurosci Ther

Acute Stress Attenuates Hepatic Ischemia-Reperfusion Injury via Hypothalamic CRH Neuron-Induced HPA Axis Activation. [Abstract]

2026 Jan;32(1):e70749. PMID: 41533055
Ecotoxicol Environ Saf

Dim blue light at night worsens high-fat diet-induced kidney damage via increasing corticosterone levels and modulating the expression of circadian clock genes. [Abstract]

2025 Jan 2:289:117636. PMID: 39752912
Biochem Pharmacol

Dexamethasone induces developmental axon damage in the offspring hippocampus by activating miR-210-3p/miR-362-5p to target the aberrant expression of Sonic Hedgehog. [Abstract]

2024 May 28:116330. PMID: 38815627
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
Cancer Immunol Immunother

Stress induces corticosterone-mediated CD8+ T cell exhaustion to promote non-small cell lung cancer. [Abstract]

2025 Sep 29;74(10):316. PMID: 41021019
Cell Biol Toxicol

Programming changes of hippocampal miR-134-5p/SOX2 signal mediate the susceptibility to depression in prenatal dexamethasone-exposed female offspring. [Abstract]

2022 Feb;38(1):69-86. PMID: 33619658
Int Immunopharmacol

Glucocorticoid signaling mitigates colitis-associated visceral hypersensitivity by suppressing 5-HT release in enterochromaffin cells via a GR-PI3K-SGK1 axis. [Abstract]

2026 Mar 1:172:116207. PMID: 41554225
Int Immunopharmacol

Escin alleviates cerebral ischemia-induced intestinal pyroptosis via the GR-dependent p38 MAPK/NF-κB signaling and NLRP3 inflammasome activation. [Abstract]

2024 Jul 1:138:112592. PMID: 38955024
Front Pharmacol

Striatal miR-183-5p inhibits methamphetamine-induced locomotion by regulating glucocorticoid receptor signaling. [Abstract]

2022 Sep 26;13:997701. PMID: 36225577
Am J Physiol Cell Physiol

cGMP-dependent protein kinase II determines β-catenin accumulation that is essential for uterine decidualization in mice. [Abstract]

2019 Dec 1;317(6):C1115-C1127. PMID: 31509448
Toxicol Sci

The role of corticosterone in nevirapine-induced idiosyncratic drug-induced liver injury. [Abstract]

2024 Jun 26;200(1):146-164. PMID: 38636494
Toxicol Sci

Prenatal Dexamethasone Exposure Induced Alterations in Neurobehavior and Hippocampal Glutamatergic System Balance in Female Rat Offspring. [Abstract]

2019 Jul 31;kfz163. PMID: 31518422
Am J Pathol

Sleep Deprivation Impairs Intestinal Mucosal Barrier by Activating Endoplasmic Reticulum Stress in Goblet Cells. [Abstract]

2024 Jan;194(1):85-100. PMID: 37918798
Int J Cancer

Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1. [Abstract]

2022 May 1;150(9):1481-1496. PMID: 34935137
Mediators Inflamm

Corticosterone Inhibits LPS-Induced NLRP3 Inflammasome Priming in Macrophages by Suppressing Xanthine Oxidase. [Abstract]

2020 May 18;2020:6959741. PMID: 32508525
Sci Rep

Spleen contributes to restraint stress induced changes in blood leukocytes distribution. [Abstract]

2017 Jul 26;7(1):6501. PMID: 28747688
iScience

Stimulation of TRPV1+ peripheral somatosensory nerves suppress inflammation via the somato-autonomic reflex. [Abstract]

2025 Jan 17;28(2):111831. PMID: 39967868
ACS Infect Dis

Mycobacterium tuberculosis Suppresses Inflammatory Responses in Host through Its Cholesterol Metabolites. [Abstract]

2024 Oct 11;10(10):3650-3663. PMID: 39360613
iScience

Glucocorticoid receptor-mediated Nr1d1 chromatin circadian misalignment in stress-induced irritable bowel syndrome. [Abstract]

2023 Jun 17;26(7):107137. PMID: 37404374
FASEB J

Exosomal Gene Biomarkers in Osteosarcoma: Mifepristone as a Targeted Therapeutic Revealed by Multi-Omics Analysis. [Abstract]

2025 Jul 15;39(13):e70809. PMID: 40616392
FEBS J

The METTL3-PGR-WNT4 axis is critical for human endometrial stromal cell decidualization. [Abstract]

2025 Jul 25. PMID: 40711993
J Virol

Dexamethasone disrupts intracellular pH homeostasis to delay coronavirus infectious bronchitis virus cell entry via sodium hydrogen exchanger 3 activation. [Abstract]

2025 May 9:e0189424. PMID: 40340398
Am J Physiol Heart Circ Physiol

Progesterone promotes endothelial nitric oxide synthase expression through enhancing nuclear progesterone receptor-SP-1 formation. [Abstract]

2020 Aug 1;319(2):H341-H348. PMID: 32618512
Toxicol Appl Pharmacol

Solasodine binds to glucocorticoid receptor to ameliorate airway remodeling and excessive autophagy in bronchial smooth muscle cells for allergic asthma. [Abstract]

2025 Mar 26:498:117313. PMID: 40154577
Exp Cell Res

Liraglutide ameliorates intrauterine adhesion by inhibiting NF-κb phosphorylation and reducing epithelial-mesenchymal transition. [Abstract]

2025 Aug 15;451(2):114708. PMID: 40784419
Neuroscience

Chronic stress disturbed the metabolism of homocysteine in mouse hippocampus and prefrontal cortex. [Abstract]

2024 Dec 17:563:63-73. PMID: 39521319
Biol Reprod

Multi-omics analysis reveals steroid hormone biosynthesis as a key pathway in advanced maternal age threatened abortion†. [Abstract]

2026 Feb 27:ioag045. PMID: 41757494
Behav Brain Res

Melatonin alleviates retrieval-induced forgetting deficits in acute sleep deprivation mice. [Abstract]

2026 Sep 13:513:116315. PMID: 42250732
Reprod Sci

Expression and Hormonal Regulation of Entpd3 at Various Estrous Cycle Stages in the Mouse Uterus. [Abstract]

2025 Apr;32(4):1033-1041. PMID: 39567465
Comp Biochem Physiol B Biochem Mol Biol

Cortisol suppresses lipopolysaccharide-induced in vitro inflammatory response of large yellow croaker (Larimichthys crocea) via the glucocorticoid receptor and p38 mitogen-activated protein kinase pathways. [Abstract]

2024 Nov 12:111046. PMID: 39542081
Biochem Biophys Res Commun

Estrogen ameliorates sepsis-induced vascular hyporeactivity in thoracic aorta of female rats via permissive effect of GRα expression. [Abstract]

2023 May 21:657:108-118. PMID: 37002984
Biochem Biophys Res Commun

Repetitive restraint stress changes spleen immune cell subsets through glucocorticoid receptor or β-adrenergic receptor in a stage dependent manner. [Abstract]

2018 Jan 1;495(1):1108-1114. PMID: 29175389
Biochem Cell Biol

Bone marrow mesenchymal stem cell-derived extracellular vesicles facilitate endometrial injury repair by carrying the E3 ubiquitin ligase WWP1. [Abstract]

2022 Aug 1;100(4):357-369. PMID: 36043683
Gen Comp Endocrinol

Roles of progesterone receptor membrane component 1 and membrane progestin receptor alpha in regulation of zebrafish oocyte maturation. [Abstract]

2018 Jul 1:263:51-61. PMID: 29649418
J Interferon Cytokine Res

Transforming Growth Factor-beta 1 Alleviates Uterine Bleeding after Medication Abortion in Early Pregnancy by Upregulating the p53/Plasminogen Activator Inhibitor-1 Pathway. [Abstract]

2025 Dec 2. PMID: 41355782
Otol Neurotol

Cortisol Sensitizes Cochlear Hair Cells to Gentamicin Ototoxicity Via Endogenous Apoptotic Pathway. [Abstract]

2024 Jan 1;45(1):e49-e56. PMID: 38085767
Loyola University Chicago

2026.
bioRxiv

Induction of menstruation in mice reveals the regulation of menstrual shedding. [Abstract]

2025 Oct 9:2025.10.08.681007. PMID: 41332577
SSRN

2025 Sep 23.
SSRN

2025 Apr 5.
University of Toronto

2024.
bioRxiv

2024 Jun 10.
Patent

US20220047602A1.
Oxid Med Cell Longev

Melatonin Ameliorates Corticosterone-Mediated Oxidative Stress-Induced Colitis in Sleep-Deprived Mice Involving Gut Microbiota. [Abstract]

2021 Jun 23:2021:9981480. PMID: 34257825
Patent

US20200129476A1
Chinese Pharmacological Bulletin

2017, 33(6): 878-882.

Mifepristone purchased from MedChemExpress. Usage Cited in: Chinese Pharmacological Bulletin. 2017, 33(6): 878-882.

Effect of RU486 on elevation of intracellular calcium induced by hydrocortisone in BV-2 cellsA a: Untreated cells; b:Cells are treated with hydro; c:Cells are treated with hydro after RU486;d: Cells are treated with RU486 only.
Evid Based Complement Alternat Med

Xiao Yao San against Corticosterone-Induced Stress Injury via Upregulating Glucocorticoid Receptor Reaction Element Transcriptional Activity. [Abstract]

2016:2016:5850739. PMID: 27822288

Mifepristone purchased from MedChemExpress. Usage Cited in: Evid Based Complement Alternat Med. 2016:2016:5850739. [Abstract]

The effects of XYS on the protein levels of Caveolin-1 (a) and GR (b) in PHN cells after corticosterone-induced stress injury.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (232.78 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3278 mL

11.6390 mL

23.2780 mL

5 mM

0.4656 mL

2.3278 mL

4.6556 mL

10 mM

0.2328 mL

1.1639 mL

2.3278 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (23.28 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

The HeLa and CaSki human cervical cancer cell lines are used. The effect of Mifepristone on proliferation of cells exposed to NSC 119875 is evaluated using the XTT assay. The assay is based on the cleavage of the yellow tetrazolium salt XTT to form an orange formazan dye by metabolically active cells. The procedure is as follows. Cells are seeded into 96-well plates; Costar at a density of 6×10³ viable cells per well in 100 μL culture medium. At the end of treatment with NSC 119875 alone or the combination of NSC 119875 plus Mifepristone, 50 μL XTT is added to each well (final concentration 0.3 mg/mL), follow by incubation for 4 h in a humidified atmosphere containing 5% CO₂ at 37˚C. The absorbance of the samples is measured spectrophotometrically at 492 nm using a microtiter plate ELISA reader^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]^[3]

Mice^[2]
Female Nude mice between 6-8 weeks of age are implanted subcutaneously with 6×10⁶ HeLa cells in a flank. Once tumors are ~5×5 mm, the animals are pair-matched into treatment and control groups. Each group consist of 8 tumor-bearing mice. The intraperitoneal administration of drugs or vehicle begin on day 0. NSC 119875, as a single agent, is administered intraperitoneally at a dose of 3 mg/kg daily on days 1 through 3; the dose of Mifepristone, as a single agent, is 2 mg/kg/day subcutaneously for 3 days; in the combination study, the mice concurrently receive NSC 119875 on the same schedule, and Mifepristone at the same dose 3 days previous to the administration of NSC 119875. The control animals receive only the vehicle. After administration of the drugs, mice are weighed and the tumors are measured with a caliper twice weekly. The tumor weight is calculated. Experiment is conducted for 74 days, after which time all animals are weighed and humanely euthanized.
Rats^[3]
Adult male Sprague-Dawley rats, weighing between 224 and 245 g upon arrival, are used. Mifepristone (20 or 40 mg/kg) or vehicle (peanut oil) are administered subcutaneously (s.c.) once daily following the 0800 administration of EtOH or control diet. Mifepristone is suspended in peanut oil and sonicated for 30 minutes at least 24 hours prior to injection, it is then stored at 4°C until needed. Suspension is vortexed for 10 to 15 minutes prior to and as needed throughout dosing.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jiang W, et al. New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids. Bioorg Med Chem. 2006 Oct 1;14(19):6726-32. [Content Brief]

[2]. Jurado R, et al. NSC 119875 cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep. 2009 Nov;22(5):1237-45. [Content Brief]

[3]. Sharrett-Field L, et al. Mifepristone Pretreatment Reduces Ethanol Withdrawal Severity In Vivo. Alcohol Clin Exp Res. 2013 Aug;37(8):1417-23. [Content Brief]

[4]. Yuehua You, et al. Progesterone Promotes Endothelial Nitric Oxide Synthase Expression Through Enhancing Nuclear Progesterone receptor-SP1 Formation. Am J Physiol Heart Circ Physiol. 2020 Jul 3. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3278 mL	11.6390 mL	23.2780 mL	58.1950 mL
	5 mM	0.4656 mL	2.3278 mL	4.6556 mL	11.6390 mL
	10 mM	0.2328 mL	1.1639 mL	2.3278 mL	5.8195 mL
	15 mM	0.1552 mL	0.7759 mL	1.5519 mL	3.8797 mL
	20 mM	0.1164 mL	0.5820 mL	1.1639 mL	2.9098 mL
	25 mM	0.0931 mL	0.4656 mL	0.9311 mL	2.3278 mL
	30 mM	0.0776 mL	0.3880 mL	0.7759 mL	1.9398 mL
	40 mM	0.0582 mL	0.2910 mL	0.5820 mL	1.4549 mL
	50 mM	0.0466 mL	0.2328 mL	0.4656 mL	1.1639 mL
	60 mM	0.0388 mL	0.1940 mL	0.3880 mL	0.9699 mL
	80 mM	0.0291 mL	0.1455 mL	0.2910 mL	0.7274 mL
	100 mM	0.0233 mL	0.1164 mL	0.2328 mL	0.5820 mL

Keywords

Mifepristone

76 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Mifepristone

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Nuclear Receptor Compound Library

Pain-Related Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Steroid Hormones Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) Mifepristone

All Endogenous Metabolite Isoforms

All NO Synthase Isoforms

Biological Activity

Chemical Information

Publications (76)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Mifepristone Related Classifications

HY-13683 Related Classifications